Clinical trialNCT05380063CompletedPhase 4Interventional

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

SponsorChina National Center for Cardiovascular DiseasesEnrollment2,300Angina PectorisBleedingCoronary Artery Bypass GraftingCoronary Artery DiseaseDual Antiplatelet TherapyMyocardial Infarction+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority, parallel controlled trial. The aim of TOP-CABG is to investigate whether de-escalated dual antiplatelet therapy (De-DAPT) is non-inferior to dual antiplatelet therapy (DAPT) in efficacy on inhibiting great saphenous vein (SVG) graft occlusion and is superior in reducing bleeding events in patients accepting coronary artery bypassing grafting.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Kai Chen
Chinese Academy of Medical Sciences, Fuwai Hospital
Study Director
clinicaltrials.gov ↗
Qing Chu, PhD
Chinese Academy of Medical Sciences, Fuwai Hospital
Study Director
clinicaltrials.gov ↗
Shengshou Hu, MD
Chinese Academy of Medical Sciences, Fuwai Hospital
Principal Investigator
clinicaltrials.gov ↗
Xin Yuan, PhD
Chinese Academy of Medical Sciences, Fuwai Hospital
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Fuwai Hospital
Beijing, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

De-escalated Dual Antiplatelet TherapyDual Antiplatelet Therapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Feb 2023
Primary completion: 8 Jul 2025
Completion: 10 Jul 2025
Last update posted: 27 Aug 2025
Registered enrollment: 2,300
Registry id: NCT05380063

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.